naa a22 4500 510764614 CHVBK 20180411083152.0 cr unu---uuuuu 180411e20131101xx s 000 0 eng 10.1007/s12094-013-1016-2 doi (NATIONALLICENCE)springer-10.1007/s12094-013-1016-2 Early volumetric change and treatment outcome of metastatic brain tumors after external beam radiotherapy: differential radiotherapy for brain metastasis [Elektronische Daten] [D. Lee, Y. Kim, C. Lee, J. Lim, C.-O. Suh, H. Kim, J. Cho] Purpose: To evaluate the treatment outcomes of low-dose whole brain radiation therapy (WBRT)-based differential radiation therapy (RT) for metastatic brain tumors. Methods: A total of 242 targets (metastatic brain lesions) were analyzed in the present study. Median WBRT dose and number of fractions were 25 (range 25-35) Gy and 10 (range 8-15) fractions, respectively. A median normalized total dose (NTD) of 1.8Gy (NTD1.8Gy) to the metastatic lesion was 45 (range 27-64.8) Gy. We numbered and contoured each metastatic lesion sequentially using computed tomography fused with serial magnetic resonance imaging to evaluate volumetric changes. Results: The 6-month and 1-year freedom from remote intracranial failure rates were 87.7 and 58.5%, respectively. The 6-month actuarial local control (LC) rate was 93.4%. Tumor diameter was a major determinant for LC, and tumor histology was a significant parameter predicting the volume reduction rate. With overall complete response (CR) rate of 56.6% after RT, CR rate, if the target was more than 1cm in size, was 25% with a median NTD1.8Gy of 45Gy, requiring dose escalation to achieve better target regression. Conclusions: Low-dose WBRT with selective boost was feasible and effective. Our results pose the rationale of future trial of differential radiation therapy (RT), which prescribes different radiation dose according to the tumor density in metastatic brain tumors. Federación de Sociedades Españolas de Oncología (FESEO), 2013 Boost nationallicence Brain nationallicence Metastases nationallicence Radiotherapy nationallicence Lee D. Department of Radiation Oncology, Yonsei Cancer Center, Severance Hospital, Yonsei University Health System, 50 Yonsei-ro, 120-752, Seodaemun-gu, Seoul, South Korea aut Kim Y. Department of Radiation Oncology, Yonsei Cancer Center, Severance Hospital, Yonsei University Health System, 50 Yonsei-ro, 120-752, Seodaemun-gu, Seoul, South Korea aut Lee C. Department of Radiation Oncology, Yonsei Cancer Center, Severance Hospital, Yonsei University Health System, 50 Yonsei-ro, 120-752, Seodaemun-gu, Seoul, South Korea aut Lim J. Department of Radiation Oncology, Yonsei Cancer Center, Severance Hospital, Yonsei University Health System, 50 Yonsei-ro, 120-752, Seodaemun-gu, Seoul, South Korea aut Suh C.-O Department of Radiation Oncology, Yonsei Cancer Center, Severance Hospital, Yonsei University Health System, 50 Yonsei-ro, 120-752, Seodaemun-gu, Seoul, South Korea aut Kim H. Department of Radiation Oncology, Yonsei Cancer Center, Severance Hospital, Yonsei University Health System, 50 Yonsei-ro, 120-752, Seodaemun-gu, Seoul, South Korea aut Cho J. Department of Radiation Oncology, Yonsei Cancer Center, Severance Hospital, Yonsei University Health System, 50 Yonsei-ro, 120-752, Seodaemun-gu, Seoul, South Korea aut Clinical and Translational Oncology Springer Milan 15/11(2013-11-01), 889-896 1699-048X 15:11<889 2013 15 12094 https://doi.org/10.1007/s12094-013-1016-2 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s12094-013-1016-2 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Lee D. Department of Radiation Oncology, Yonsei Cancer Center, Severance Hospital, Yonsei University Health System, 50 Yonsei-ro, 120-752, Seodaemun-gu, Seoul, South Korea aut NATIONALLICENCE 700 1- Kim Y. Department of Radiation Oncology, Yonsei Cancer Center, Severance Hospital, Yonsei University Health System, 50 Yonsei-ro, 120-752, Seodaemun-gu, Seoul, South Korea aut NATIONALLICENCE 700 1- Lee C. Department of Radiation Oncology, Yonsei Cancer Center, Severance Hospital, Yonsei University Health System, 50 Yonsei-ro, 120-752, Seodaemun-gu, Seoul, South Korea aut NATIONALLICENCE 700 1- Lim J. Department of Radiation Oncology, Yonsei Cancer Center, Severance Hospital, Yonsei University Health System, 50 Yonsei-ro, 120-752, Seodaemun-gu, Seoul, South Korea aut NATIONALLICENCE 700 1- Suh C.-O Department of Radiation Oncology, Yonsei Cancer Center, Severance Hospital, Yonsei University Health System, 50 Yonsei-ro, 120-752, Seodaemun-gu, Seoul, South Korea aut NATIONALLICENCE 700 1- Kim H. Department of Radiation Oncology, Yonsei Cancer Center, Severance Hospital, Yonsei University Health System, 50 Yonsei-ro, 120-752, Seodaemun-gu, Seoul, South Korea aut NATIONALLICENCE 700 1- Cho J. Department of Radiation Oncology, Yonsei Cancer Center, Severance Hospital, Yonsei University Health System, 50 Yonsei-ro, 120-752, Seodaemun-gu, Seoul, South Korea aut NATIONALLICENCE 773 0- Clinical and Translational Oncology Springer Milan 15/11(2013-11-01), 889-896 1699-048X 15:11<889 2013 15 12094 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer